ReviewVaccines2023
Systematic Review on the Efficacy, Effectiveness, Safety, and Immunogenicity of Monkeypox Vaccine.
Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global epidemiology, viral evolution, and public health responses: a systematic review on Mpox (1958-2024).Journal of global health · 2025Pooled it
- Toward Precision Vaccinology for Mpox: Rational Antigen Design, Next-Generation Platforms, and Immune Correlates of Protection.Tropical medicine and infectious disease · 2026Review
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- Tandem triplicate A29L peptide elicits robust immune responses against monkeypox virus in mice.Applied microbiology and biotechnology · 2026Article
- CircRNA based bi-antigen vaccines against mpox virus induce potent and durable cross-protection in mice.Molecular biomedicine · 2026Article
- The Emerging Threat of Monkeypox: An Updated Overview.Viruses · 2026Review
- Comparative humoral profiles in mpox cases, survivors, and vaccinated individuals reveal correlates of protection against MPXV.Cell reports. Medicine · 2025Article
- Review
- Review
- Advancing the understanding and management of Mpox: insights into epidemiology, disease pathways, prevention, and therapeutic strategies.BMC infectious diseases · 2025Review
- Psychosocial correlates of free Mpox vaccination intention among men who have sex with men in China: model construction and validation.Journal of global health · 2025Article
- Epidemiology and Clinical Features of Mpox in Jakarta, Indonesia, August 2022-December 2023.Vaccines · 2025Article
- Mpox: current knowledge and understanding-a scoping review.FEMS microbiology reviews · 2025Article
- Current status of next-generation vaccines against mpox virus: a scoping review.Frontiers in pharmacology · 2025Review
- Comprehensive Insights into Monkeypox (mpox): Recent Advances in Epidemiology, Diagnostic Approaches and Therapeutic Strategies.Pathogens (Basel, Switzerland) · 2024Review
- The intention of Egyptian healthcare workers to take the monkeypox vaccine: is urgent action required?BMC health services research · 2024Article
- Article
- Ethical considerations during Mpox Outbreak: a scoping review.BMC medical ethics · 2024Article
- Global prevalence and correlates of mpox vaccine acceptance and uptake: a systematic review and meta-analysis.Communications medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe variation in the reported vaccine safety and effectiveness could contribute to the high rates of vaccine hesitancy among the general population and healthcare workers in areas where monkeypox (mpox) is circulating. In this review, our objective was to evaluate the safety, immunogenicity, effectiveness, and efficacy of the mpox vaccines.
methodsAn extensive search for articles across multiple databases was performed, including searching six databases (PubMed Central, PubMed Medline, Scopus, Web of Science, Cochrane, ProQuest), two pre-print databases (European PMC Preprint and MedRxiv), and Google Scholar.
resultsA total of 4290 citations were retrieved from the included databases. Following the removal of duplicates and the initial screening of records, a total of 36 studies were included into the analysis. Additionally, we identified five more studies through manual searches, resulting in a total of 41 eligible articles for qualitative synthesis. The study findings revealed that mpox vaccines demonstrate the ability to generate adequate antibodies; however, their effectiveness may decrease over time, exhibiting varying safety profiles. Most of the included studies consistently reported substantial levels of effectiveness and efficacy against mpox. Interestingly, the number of vaccine doses administered was found to influence the degree of immunogenicity, subsequently impacting the overall effectiveness and efficacy of the vaccines. Furthermore, we found that smallpox vaccines exhibited a form of cross-protection against mpox.
conclusionsVaccines can be used to prevent mpox and effectively control its spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.